MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$2.81 USD
-0.01 (-0.35%)
Updated Jul 9, 2024 02:22 PM ET
After-Market: $2.81 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MEIP 2.81 -0.01(-0.35%)
Will MEIP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MEIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MEIP
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
MEIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails
Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion
Other News for MEIP
12 Health Care Stocks Moving In Thursday's After-Market Session
Stifel Nicolaus Reaffirms Their Hold Rating on MEI Pharma (MEIP)
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
MEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024
MEI Pharma GAAP EPS of -$1.37 beats by $0.12